TOT BIOPHARM International Resultados de beneficios anteriores
Pasado controles de criterios 2/6
TOT BIOPHARM International has been growing earnings at an average annual rate of 47.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 74.7% per year. TOT BIOPHARM International's return on equity is 1.2%, and it has net margins of 0.9%.
Información clave
47.3%
Tasa de crecimiento de los beneficios
56.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.0% |
| Tasa de crecimiento de los ingresos | 74.7% |
| Rentabilidad financiera | 1.2% |
| Margen neto | 0.9% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07
The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03Desglose de ingresos y gastos
Cómo gana y gasta dinero TOT BIOPHARM International. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 973 | 9 | 589 | 100 |
| 31 Mar 24 | 877 | -14 | 549 | 102 |
| 31 Dec 23 | 781 | -38 | 509 | 104 |
| 30 Sep 23 | 684 | -44 | 454 | 117 |
| 30 Jun 23 | 588 | -49 | 400 | 131 |
| 31 Mar 23 | 515 | -50 | 333 | 141 |
| 31 Dec 22 | 442 | -50 | 267 | 151 |
| 30 Sep 22 | 339 | -106 | 202 | 174 |
| 30 Jun 22 | 235 | -162 | 137 | 196 |
| 31 Mar 22 | 156 | -212 | 108 | 205 |
| 31 Dec 21 | 76 | -261 | 79 | 215 |
| 30 Sep 21 | 54 | -268 | 76 | 220 |
| 30 Jun 21 | 33 | -274 | 73 | 225 |
| 31 Mar 21 | 28 | -281 | 73 | 230 |
| 31 Dec 20 | 22 | -288 | 73 | 235 |
| 30 Sep 20 | 28 | -301 | 93 | 225 |
| 30 Jun 20 | 34 | -313 | 113 | 215 |
| 31 Mar 20 | 40 | -306 | 120 | 203 |
| 31 Dec 19 | 45 | -299 | 127 | 191 |
| 31 Dec 18 | 39 | -268 | 94 | 189 |
| 31 Dec 17 | 52 | -149 | 53 | 106 |
Ingresos de calidad: 1875 has a large one-off loss of CN¥2.5M impacting its last 12 months of financial results to 30th June, 2024.
Margen de beneficios creciente: 1875 became profitable in the past.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 1875 has become profitable over the past 5 years, growing earnings by 47.3% per year.
Acelerando crecimiento: 1875 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Beneficios vs. Industria: 1875 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rentabilidad financiera
Alta ROE: 1875's Return on Equity (1.2%) is considered low.